S56 - MS Trials and Treatment
| Event Time: | Friday May 10, 2019 1:00 pm to 3:00 pm |
| Topic(s): | MS and CNS Inflammatory Disease |
| Director(s): | |
| Description: | |
| Completion Message: | |
| CME Credits: | 2 |
| Core Competencies: |
| Start/End Time | Title | Faculty |
|---|---|---|
| 2:40 PM - 3:00 PM | Q&A Panel with Authors | Faculty |
| Speaker | Disclosure |
|---|
| Start Time | Pub. | Title | Presenter |
|---|---|---|---|
| 1:00 PM | 001 | A Phase 1, Multiple-dose Study of Elezanumab (ABT-555) in Patients with Relapsing Forms of Multiple Sclerosis |
Disclosure: Dr. Ziemann has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AbbVie. Dr. Ziemann holds stock and/or stock options in AbbVie which sponsored research in which Dr. Ziemann was involved as an investigator. .
|
| 1:00 PM | 002 | Immune tolerance in patients with Multiple Sclerosis and Neuromyelitis Optica by peptide-loaded tolerogenic dendritic cells: final results of the phase 1b clinical trial and extension |
Disclosure: Dr. Zubizarreta has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Genzyme, Biogen, Merck and Bayer-Schering.
|
| 1:00 PM | 003 | A Phase 1b, open-label study to evaluate the safety and tolerability of the putative remyelinating agent, liothyronine, in individuals with multiple sclerosis |
Disclosure: Dr. Newsome has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Celgene, EMD Serono, Genentech, medDay Pharmaceuticals, and Gerson Lehrman Group.. Dr. Newsome has received research support from Biogen, Genentech, Department of Defense, the National MS Society, and Patient-Centered Outcomes Research Institute.
|
| 1:00 PM | 004 | Efficacy and Safety of the Bruton’s Tyrosine Kinase Inhibitor Evobrutinib (M2951) in Patients with Relapsing Multiple Sclerosis over 48 Weeks: a Randomized, Placebo-Controlled, Phase 2 Study |
Disclosure: Dr. Montalban has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Dr. Montalban received speaking honoraria and travel expenses for scientific meetings, has been a steering committee member of clinical trials or participated in advisory boards of clinical trials in the past 3 years with Biogen, Merck Serono, Genentech, Genzyme, Novartis, Sanofi-Aventis, Teva Pharmaceuticals, Roche, Celgene, Actelion, NMSS and MSIF.
|
| 1:00 PM | 005 | Short-term brain damage accrual in African Americans with Multiple Sclerosis: MRI Findings from the CombiRx trial |
Disclosure: Dr. Petracca has nothing to disclose.
|
| 1:00 PM | 006 | Neurofilament Light Chains as a Marker of Concurrent and Future Active Disease in Relapsing Multiple Sclerosis: An Analysis of Baseline Data From the Phase 3 Ozanimod Clinical Trials |
Disclosure: Dr. Harris has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Celgene Corporation.
|
| 1:00 PM | 007 | One-year interim analysis results of the Phase IIIb CHORDS study evaluating ocrelizumab effectiveness and safety in patients with relapsing-remitting multiple sclerosis who had suboptimal response with prior disease-modifying treatments |
Disclosure: Dr. Leist has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Genentech, Biogen, EMD Serono, Teva, Sanofi-Genzyme, Bayer. Dr. Leist has received research support from Johnson and Johnson (Acelion); Novartis, Biogen, Chugai, Alkermes, Genentech,Acorda, Bayer, Biogen, Daiichi, EMD Serono, Novartis, ONO, Pfizer and Teva Neuroscience.
|
| 1:00 PM | 008 | Ocrelizumab treatment reduced levels of neurofilament light chain and numbers of B cells in the cerebrospinal fluid of patients with relapsing multiple sclerosis in the OBOE study |
Disclosure: Dr. Cross has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Celgene, EMD Serono, Genzyme, Genentech, Novartis, Roche, TG Therapeutics. Dr. Cross has received research support from Genentech, EMD Serono.
|
| 1:00 PM | 009 | Efficacy and Safety of Fingolimod 0.5 mg and 0.25 mg Versus Glatiramer Acetate 20 mg in Patients with Relapsing-Remitting Multiple Sclerosis - ASSESS Study Group |
Disclosure: Dr. Cree has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Abbvie, Akili, Alexion, Biogen, EMD Serono, Novartis, Sanofi Genzyme and TG Therapeutics..
|
Ready to register for the 2019 AAN Annual Meeting?
Related Courses
| 9:30 AM-11:30 AM |
|---|
|
C19 -
Multiple Sclerosis Overview I: Clinical Pearls
Mary Willis MD |
| 1:30 PM-3:30 PM |
|
C29 -
Multiple Sclerosis Overview II: Clinical Advances
Scott Newsome DO, FAAN |
| 7:00 AM-9:00 AM |
|---|
|
C44 -
Multiple Sclerosis Therapy: Symptom Management
Andrew Solomon MD |
| 9:15 AM-12:00 PM |
|
Presidential Plenary Session
Natalia Rost MD, MPH, FAAN, FAHA |
| 11:30 AM-6:30 PM |
|
P1 -
Poster Session 1
|
| 1:00 PM-3:00 PM |
|
C49 -
Neurology Update I: Multiple Sclerosis, Sleep, and Neuromuscular Disease
Ralph Jozefowicz MD, FAAN, Adam Quick MD |
|
C56 -
Multiple Sclerosis Therapy: Disease-modifying Treatment I
Scott Newsome DO, FAAN |
|
S6 -
MS and CNS Inflammatory Disease: Clinical Considerations I
|
| 3:30 PM-5:30 PM |
|
C73 -
Multiple Sclerosis Therapy: Disease-modifying Treatment II
John Rose MD, FAAN |
| 7:00 AM-9:00 AM |
|---|
|
C86 -
Neuromyelitis Optica Spectrum Disorders
Dean Wingerchuk MD, FAAN |
| 9:15 AM-12:00 PM |
|
Contemporary Clinical Issues Plenary Session
Randolph Marshall MD, FAAN |
| 11:30 AM-6:30 PM |
|
P2 -
Poster Session 2
|
| 1:00 PM-3:00 PM |
|
C100 -
Esclerosis Múltiple y Otras Enfermedades Inflamatorias Desmielinizantes y Autoinmunes del Sistema Nervioso Central (MS and Other Demyelinating Inflammatory and Autoimmune Central Nervous System Disorders)
Lilyana Amezcua MD, FAAN |
|
S12 -
Progressive Multiple Sclerosis
|
| 3:30 PM-5:30 PM |
|
S19 -
Child Neurology: Updates in Autism, Migraine, MS, and Stroke
|
| 7:00 AM-9:00 AM |
|---|
|
C130 -
Diagnostic Pearls in Myelitis: a Case-based Approach
Eoin Flanagan MBBCh |
| 9:15 AM-11:30 AM |
|
Clinical Trials Plenary Session
Deborah Hall MD, PhD, FAAN, Holly Hinson MD, MCR, FAAN |
| 11:30 AM-6:30 PM |
|
P3 -
Poster Session 3
|
| 1:00 PM-3:00 PM |
|
N3 -
Neuroscience in the Clinic: Stem Cells
Paul George MD, PhD, MSE, Antonio Omuro MD |
|
S26 -
MS and CNS Inflammatory Disease: Clinical Considerations II
|
| 3:30 PM-5:30 PM |
|
S31 -
MS and CNS Inflammatory Disease: Imaging
|
| 9:15 AM-11:30 AM |
|---|
|
Frontiers in Neuroscience Plenary Session
Paul George MD, PhD, MSE |
| 11:30 AM-6:30 PM |
|
P4 -
Poster Session 4
|
| 1:00 PM-3:00 PM |
|
C181 -
Treatment of Pediatric Multiple Sclerosis in the Current Era
Brenda Banwell MD, FAAN |
|
S37 -
MS Biomarkers
|
| 3:30 PM-5:30 PM |
|
Presentation of the John Dystel Prize for Multiple Sclerosis Research
|
| 3:45 PM-4:15 PM |
|
Update on the Complementary Therapies for MS: An Evidence-based Review
Vijayshree Yadav MD, FAAN |
| 11:30 AM-6:30 PM |
|---|
|
P5 -
Poster Session 5
|
| 12:00 PM-12:45 PM |
|
A "How to and Why" of the Shared Medical Appointments: A Way to Meet the Needs of the Patient and Provider While Maximizing Clinical Time
Mary Rensel MD, FAAN, Nancy Isenberg MD, MPH, FAAN |
| 1:00 PM-3:00 PM |
|
S49 -
MS Epidemiology and Risk Stratification
|
| 3:30 PM-5:30 PM |
|
S55 -
MS Basic Science
|
| 7:00 AM-9:00 AM |
|---|
|
C248 -
Multiple Sclerosis in the Trenches: Controversy and Consensus in Clinical Decision-Making
Aaron Miller MD, FAAN |
| 9:15 AM-11:30 AM |
|
Neurology Year in Review Plenary Session
Martinson Arnan MD |
| 1:00 PM-3:00 PM |
| 3:30 PM-4:30 PM |
|
C258 -
Education Blitz: Multiple Sclerosis
Stephen Krieger MD, FAAN |